期刊
EMERGING MICROBES & INFECTIONS
卷 9, 期 1, 页码 757-760出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/22221751.2020.1746200
关键词
COVID-19; hypertension; Renin-angiotensin system; angiotensin-converting enzyme inhibitors; angiotensin II type1 receptor blockers
资金
- National Natural Science Foundation of China [81873958]
- China Postdoctoral Science Foundation [2019M653108]
- National Science and Technology Major Project for Control and Prevention of Major Infectious Diseases of China [2017ZX10103004]
- State Key Laboratory of Respiratory Diseases Open Project [SKLRD-OP-201919]
- Sanming Project of Medicine in Shenzhen [SZSM201911009]
The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes remains unknown. COVID-19 patients with hypertension were enrolled to evaluate the effect of RAS inhibitors. We observed that patients receiving ACEI or ARB therapy had a lower rate of severe diseases and a trend toward a lower level of IL-6 in peripheral blood. In addition, ACEI or ARB therapy increased CD3 and CD8 T cell counts in peripheral blood and decreased the peak viral load compared to other antihypertensive drugs. This evidence supports the benefit of using ACEIs or ARBs to potentially contribute to the improvement of clinical outcomes of COVID-19 patients with hypertension.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据